Key lawmakers say upcoming hearings on lender failures intention to enhance U.S. self-assurance in banking sector

Key lawmakers say upcoming hearings on lender failures intention to enhance U.S. self-assurance in banking sector


Critical Details
  • Back again-to-again congressional hearings on the failures of Silicon Valley Financial institution and Signature Financial institution next week will bring “a fantastic deal of certainty and self-confidence to the market place,” said Property Economical Services Committee Chairman Patrick McHenry.
  • Committee Democrats are pushing for much more oversight of banking companies by laws, while Republicans lay the blame for the institutions’ collapse on regulators.
  • Sen. Sherrod Brown, an Ohio Democrat and chairman of the Senate Banking Committee, reported banking lobbyists need to not push to loosen oversight all through the banking disaster.



Source

Here are 3 forces that drove the stock market during Wall Street’s comeback week
Finance

Here are 3 forces that drove the stock market during Wall Street’s comeback week

The stock market staged a comeback last week, even as Wall Street waded through a flurry of both upbeat and unsettling headlines. The Nasdaq broke its five-week losing streak on Friday, buoyed by strong advances from our big tech names like Meta Platforms , Nvidia and Amazon . The tech-heavy index ended the week 1.9% […]

Read More
Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’
Finance

Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’

ETF Edge Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’ Published Sat, Feb 21 202611:00 AM EST Blair Bao WATCH LIVE Source

Read More
Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more
Finance

Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more

Check out the companies making headlines before the bell. Grail — Shares cratered 47% after the company said a trial of one of its drugs missed its primary endpoint and failed to show statistically significant Stage III-IV cancer reduction. Blue Owl Capital — Shares slid nearly 3%, a day after after the private market and […]

Read More